Interdisciplinary Tumor Board
Our inter-institutional and interdisciplinary tumor board focused on cutaneous lymphomas, melanoma, and other advanced skin malignancies, such as Kaposi sarcoma, Merkel cell carcinoma, and squamous cell carcinoma, serves as a crucial platform for collaborative patient care and cutting-edge research. Led by Dr. Larisa Geskin, the tumor board brings together leading specialists from Columbia and Cornell to comprehensively evaluate complex cases and develop individualized treatment plans.
Our tumor board is composed of renowned experts across dermatology, internal medicine, surgical oncology, radiation oncology, and dermatopathology. Oncology experts include:
- Larisa Geskin, MD (Dermatology/Oncology)
- Barbara Pro, MD (Hematology/Oncology)
- Alejandro Gru, MD (Dermatopathology)
- Mikhail Doubrovin, MD (Radiology, Nuclear Medicine)
- Faramarz Samie, MD, PhD (Dermatologic Surgery)
- David Horowitz, MD (Radiation Oncology)
- Bret Taback, MD (Surgical Oncology)
- Michael Kluger, MD (Surgical Oncology)
- Mariam El-Ashmawy, MD, PhD (Medical Oncology)
- Benjamin Izar, MD, PhD (Medical Oncology)
- Paul Chapman, MD (Medical Oncology)
- Jedd Wolchok, MD, PhD (Immuno-Oncology)
- Anna Pavlik, DO (Medical Oncology)
- Niroshana Anandasabapathy, MD, PhD (Dermatology/Immunology)
Together, the boards handle a wide spectrum of cases, with a special focus on lymphoma and melanoma, as well as other advanced skin cancers.
Through regular, structured meetings, we ensure that each patient benefits from the combined expertise of all specialties involved, streamlining diagnosis and care. Additionally, we emphasize interdisciplinary studies that aim to advance treatment protocols and emerging therapies for skin cancers. This comprehensive approach optimizes patient outcomes and fosters innovation in clinical and translational research, positioning our group as a leader in the field of cutaneous oncology.
This tumor board's commitment to interdisciplinary collaboration, patient-centered care, and innovative research makes it a powerful tool for improving skin cancer care across institutional lines.